Cadence Raises $100M Series C at $1.2B Valuation

Cadence closed a $100M Series C led by Spark Capital at a $1.2B valuation, now serving 100,000 chronic-care patients and saving Medicare $2.7M weekly.

Lead

What Happened

Cadence's platform deploys supervised AI agents that monitor patient vitals daily, flag clinical deterioration early, support timely medication adjustments, and deliver personalized lifestyle coaching — all between scheduled clinic visits. The company currently serves more than 100,000 active patients across 21 major health systems, with clinical outcomes documented in peer-reviewed literature.

Alongside the funding, Cadence announced new health system affiliations with Duke Health and Texas Health Resources, extending its geographic footprint into the Southeast and South-Central United States.

Financial Performance

The Series C closes on an exceptional growth trajectory. Cadence tripled annual recurring revenue in 2025 and projects annualized revenue of $140 million by the end of 2026. The company estimates its platform saves Medicare roughly $2.7 million every week by reducing avoidable hospitalizations, emergency department visits, and duplicative care for beneficiaries managing chronic conditions including hypertension, diabetes, and heart failure.

Strategic Context

Chronic disease management for older adults represents one of the largest and most structurally underserved segments in U.S. healthcare. Medicare beneficiaries account for a disproportionate share of national healthcare spending, driven primarily by the difficulty of sustaining consistent monitoring and intervention between quarterly or annual physician visits. Cadence's supervised AI agent model creates a continuous care layer on top of existing health system infrastructure without requiring patients to change providers.

The participation of Corewell Health Ventures, Memorial Hermann, and Duke Health as investors signals a structural shift in health system strategy. Rather than building proprietary healthAI capabilities internally, major hospital networks are increasingly anchoring capital to external platforms with demonstrated clinical and financial outcomes at scale. The dual role of Duke Health — as both investor and new operating affiliate — deepens the alignment between Cadence and the institutions it serves, reducing adoption friction that has historically slowed enterprise health technology deployments.

AI and Technology Angle

Cadence's supervised AI agents occupy a deliberate middle position in the healthAI landscape — more autonomous than conventional remote patient monitoring tools but subject to clinician oversight that limits regulatory and liability exposure under current frameworks. The agents ingest daily biometric data, apply risk stratification models, and surface recommended interventions to care teams, who retain final decision authority.

That architecture has allowed Cadence to scale without triggering the FDA's more stringent pathways for fully autonomous clinical decision support. As AI capabilities advance and regulators develop clearer guidance for agentic health applications, the company's supervised model positions it to expand agent autonomy incrementally — a structural advantage over platforms that began with fully manual workflows and must redesign systems to accommodate automation.

What Comes Next

Cadence will deploy the new capital across three priorities: expanding into additional health systems, advancing AI agent capabilities, and accelerating growth within value-based care contracts where payers and providers share downside risk on total cost of care. Value-based arrangements are particularly favorable for Cadence's model; savings generated per patient translate directly into revenue rather than simply reducing fee-for-service volume, creating a durable alignment of financial incentives between the company and its health system partners.

Outlook

Cadence enters the second half of 2026 with a scaled patient base, strong revenue momentum, and a syndicate that blends financial and strategic capital. Its ability to demonstrate peer-reviewed clinical outcomes alongside system-level cost reductions positions it favorably as health systems face intensifying pressure to manage chronic disease populations more efficiently within constrained operating budgets. Near-term growth will hinge on converting new health system affiliations into active patient volumes and on broadening penetration within value-based care arrangements where the platform's Medicare savings proposition is most directly monetizable.